Comparison of Adverse Events Following Immunisation with acellular and Whole-Cell Pertussis Vaccines: A Systematic Review

Simple item page
dc.contributor.authorPatterson, Jenna
dc.contributor.authorKagina, Benjamin M.
dc.contributor.authorHussey, Gregory D.
dc.contributor.authorMuloiwa, Rudzani
dc.date.accessioned2023-02-15T19:09:43Z
dc.date.available2023-02-15T19:09:43Z
dc.date.issued2018
dc.description.abstractTwo types of vaccines are currently licensed for use against pertussis: whole-cell (wP) and acellular pertussis (aP). There is evidence that wP confers more durable immunity than aP, however wP has been more frequently associated with adverse events following immunisation (AEFI). A comparison of the frequency of AEFI with the first doses of wP and aP has not yet been clearly documented. This must be done in light of recent considerations to move towards a wP prime-aP boost vaccination strategy in low and middle-income countries. To compare the frequency of AEFI associated with the first dose of the wP and aP vaccines. We also compared the frequency of AEFI associated with subsequent doses of wP. This systematic review was carried out in strict accordance with the published protocol. High heterogeneity amongst included one-armed studies did not allow for pooling of prevalence estimates. The prevalence estimates of AEFI at first vaccine dose of wP ranged from 0 to 75%, while the prevalence estimates of AEFI at first vaccine dose of aP ranges from 0 to 39%. The prevalence estimates of adverse events following second and third vaccine dose of wP ranged from 0 to 71% and 0 to 61%, respectively. Risk ratios among two-armed studies showed an increased risk of adverse events with first dose of wP compared to aP [local reaction RR 2.73 (2.33, 3.21), injection site pain RR 4.15 (3.24, 5.31), injection site swelling RR 4.38 (2.70, 7.12), fever over 38 °C RR 9.21 (5.39, 15.76), drowsiness RR 1.34 (1.18, 1.52) and vomiting RR 1.28 (0.91, 1.79)]. Our results confirm that, when comparing the first dose, wP is more reacotgenic than aP. The proposed wP prime followed by aP boost pertussis vaccine strategy should be approached with caution.en_US
dc.identifier.citationPatterson, J., Kagina, B. M., Gold, M., Hussey, G. D., & Muloiwa, R. (2018). Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine, 36(40), 6007-6016.https://doi.org/10.1016/j.vaccine.2018.08.022en_US
dc.identifier.issn0264-410X
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/7808
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectPertussisen_US
dc.subjectWhole-cell pertussisen_US
dc.subjectAcellular pertussisen_US
dc.subjectInfectious diseasesen_US
dc.titleComparison of Adverse Events Following Immunisation with acellular and Whole-Cell Pertussis Vaccines: A Systematic Reviewen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines A systematic review.pdf
Size:
1.61 MB
Format:
Adobe Portable Document Format
Description:
Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences